Is This the Best Coronavirus Stock to Buy Now?
Novavax (NASDAQ: NVAX) is a small-cap biotech company that has been at the forefront of the development of a vaccine for COVID-19. The company's shares are up by a whopping 500% since the beginning of the year, easily outpacing the return of the S&P 500, which is down by 11.5% year to date.
Investors are hopeful that Novavax will make a fortune off its potential vaccine for COVID-19. However, as several other biotech companies are looking to develop vaccines or treatments for COVID-19, betting that Novavax will win that race is a bit speculative at this point. Still, there is another potential catalyst for Novavax on the way, and this arguably makes the company worth a second look.
Novavax focuses on the development of vaccines for infectious diseases. The company does not currently have any products on the market, but one of its lead pipeline candidates is a potential flu vaccine called NanoFlu, which is being developed specifically for adults over the age of 65.
Source Fool.com
